IFN-α blocks IL-17 production by peripheral blood mononuclear cells in Behçet's disease

Rheumatology

Volumn 50, Issue 2, 2011, Pages 293-298

  Liu, Xiaoli ^a,b   Yang, Peizeng ^a   Wang, Chaokui ^a   Li, Fuzhen ^a   Kijlstra, Aize ^c  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Beh et's disease; IFN ; IL 10; IL 17

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

ADULT; ARTICLE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; BEHCET SYNDROME; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-17; LEUKOCYTES, MONONUCLEAR; MALE;

EID: 78751694243     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq330     Document Type: Article

References (30)

1. Yang P, Zhang Z, Zhou H et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res 2005;30:943-8.
2. Bonfioli AA, Orefice F. Behçet's disease. Semin Ophthalmol 2005;20:199-206.
3. Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A. Clinical features of Chinese patients with Behçet's disease. Ophthalmology 2008;115:312-8.e314.
4. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005;50: 297-350.
5. Suzuki Kurokawa M, Suzuki N. Behcet's disease. Clin Exp Med 2004;4:10-20.
6. Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M. Behcet's disease: ocular effects and treatment. Prog Retin Eye Res 2008;27:111-36.
7. Chi W, Zhu X, Yang P et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008;49:3058-64.
8. Hirohata S, Shibuya H, Tejima S. Suppressive influences of IFN-alpha on IL-17 expression in human CD4+ T cells. Clin Immunol 2010;134:340-4.
9. + T cells and monocytes. Blood 1996;87:4731-6.
10. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.
11. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 1995;154:1280-6.
12. Fitzgerald DC, Zhang GX, El-Behi M et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007;8:1372-9.
13. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335: 1078-80.
14. Meyer O. Interferons and autoimmune disorders. Joint Bone Spine 2009;76:464-73.
15. Moraga I, Harari D, Schreiber G, Uze G, Pellegrini S. Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol 2009;29:4778-87.
16. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol 2009;182:3928-36.
17. Penton-Rol G, Cervantes-Llanos M, Cabrera-Gomez JA et al. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Int Immunopharmacol 2008;8: 881-6.
18. Kubota N, Ebihara T, Matsumoto M et al. IL-6 and IFN-alpha from dsRNA-stimulated dendritic cells control expansion of regulatory T cells. Biochem Biophys Res Commun 2010;391:1421-6.
19. Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV. Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 2006;47:3946-50.
20. Finter NB, Chapman S, Dowd P et al. The use of interferon-alpha in virus infections. Drugs 1991;42: 749-65.
21. Raziuddin S, al-Dalaan A, Bahabri S et al. Divergent cytokine production profile in Behcet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998;25: 329-33.
22. Hamzaoui K, Hamzaoui A, Guemira F et al. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002;31:205-10.
23. Aridogan BC, Yildirim M, Baysal V et al. Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behcet's disease. J Dermatol 2003;30:602-7.
24. Pirhonen J, Siren J, Julkunen I, Matikainen S. IFN-alpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J Leukoc Biol 2007; 82:1185-92.
25. Diveu C, McGeachy MJ, Boniface K et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol 2009;182:5748-56.
26. Cui Y, Shao H, Lan C et al. Major role of gamma delta T cells in the generation of IL-17+ uveitogenic T cells. J Immunol 2009;183:560-7.
27. Kotter I, Koch S, Vonthein R et al. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 2005;23:S20-6.
28. Strengell M, Julkunen I, Matikainen S. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol 2004;76:416-22.
29. Spolski R, Kim HP, Zhu W et al. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol 2009;182:2859-67.
30. Wan L, Lin CW, Lin YJ et al. Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J Cell Mol Med 2008;12:876-88.